AbobotulinumtoxinA provides flexibility for the treatment of cervical dystonia with 500 U/1 mL and 500 U/2 mL dilutions

INTRODUCTION: Cervical dystonia (CD) is a neurologic movement disorder with potentially disabling effects and significant impact on quality of life of those affected. AbobotulinumtoxinA (aboBoNT-A) was initially approved for a dilution of 500 U/1 mL and subsequently for a dilution of 500 U/2 mL, pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Lew, Mark F., Hauser, Robert A., Isaacson, Stuart H., Truong, Daniel, Patel, Atul T., Brashear, Allison, Ondo, William, Maisonobe, Pascal, Dashtipour, Khashayar, Bahroo, Laxman, Wietek, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636802/
https://www.ncbi.nlm.nih.gov/pubmed/34888518
http://dx.doi.org/10.1016/j.prdoa.2021.100115

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636802/
https://www.ncbi.nlm.nih.gov/pubmed/34888518
http://dx.doi.org/10.1016/j.prdoa.2021.100115

Ejemplares similares